GI-128 / GI Innovation - LARVOL DELTA

Discovery and characterization of GI-128: A PD-L1 x LILRB1/2/4 bispecific antibody as a macrophage engager (AACR 2026) - "These findings suggest that GI-128, a bispecific macrophage engager, has a promising potential to reinvigorate tumoricidal macrophage function in immunosuppressed PD-L1-positive tumors. In vivo anti-tumor efficacy of GI-128 is being investigated."

Bispecific • IO biomarker • Oncology • LILRB1 • LILRB2 • LILRB4

GI Innovation decides to increase capital by allocating 80 billion won to shareholders [Google translation] (Hankyung) - "GI Innovation is conducting a paid-in capital increase with shareholder allocation of 80 billion won...The new share allocation base date is February 12, 2025, the listing date is April 10, 2025, and Korea Investment & Securities will be the lead manager for the paid-in capital increase....The company plans to use the raised funds for Korean/US phase 1/2 clinical trials of immunotherapy drugs GI-101A and GI-102, clinical trials of metabolism-modulating anticancer drug GI-108, R&D of new pipelines such as GI-305, GI-213, and GI-128 other operating funds, etc."

Financing • Solid Tumor

GI Innovation Selected for 2 National New Drug Development Projects [Google translation] (HIT News) - "GI Innovation announced on the 26th that it had been selected for two projects in the 2nd National New Drug Development Project in 2024 by the National Drug Development Fund...The projects selected this time are 'New Drug Clinical Development Phase 2 Clinical Trial' and 'New Drug-Based Expansion Research Leading Material Phase'. For the New Drug Clinical Development Phase 2 Clinical Trial, we will receive research support for two years in cooperation with Professor Seung-Tae Kim of...Samsung Seoul Hospital, with the goal of obtaining GI-102 technology transfer and accelerated approval....In addition, the next-generation multi-target macrophage regulator GI-128 was selected for the new drug-based expansion research lead substance project. This project will receive research support for two years with the goal of developing an optimized lead candidate substance and quickly entering the non-clinical stage and early technology transfer."

Financing • New P2 trial • Oncology • Solid Tumor